References
- Cook C, Foster P. Epidemiology of glaucoma: what's new? Can J Ophthalmol 2012;47:223–226
- Goldmann H, Schmidt T. [Applanation tonometry]. Ophthalmologica 1957;134:221–242
- Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714–720; discussion 829–830
- Herndon LW, Weizer JS, Stinnett SS. Central corneal thickness as a risk factor for advanced glaucoma damage. Arch Ophthalmol 2004;122:17–21
- Al-Jazzaf AM, DeSantis L, Netland PA. Travoprost: a potent ocular hypotensive agent. Drugs Today (Barc) 2003;39:61–74
- Viestenz A, Martus P, Schlotzer-Schrehardt U, Langenbucher A, Mardin CY. [Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness -- a cross-sectional study on 403 eyes]. Klin Monbl Augenheilkd 2004;221:753–756
- Crichton AC, Harasymowycz P, Hutnik CM, Behki R, Boucher S, Ibrahim F, et al. Effectiveness of dorzolamide-timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line study. J Ocul Pharmacol Ther 2010;26:503–511
- Lass JH, Khosrof SA, Laurence JK, Horwitz B, Ghosh K, Adamsons I. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group. Arch Ophthalmol 1998;116:1003–1010
- Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology 2008;115:790–5 e4
- Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci 2003;44:715–721
- Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008; 53:S107–S120
- Lindsey JD, Kashiwagi K, Boyle D, Kashiwagi F, Firestein GS, Weinreb RN. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res 1996;15:869–875
- Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 1998;67:179–191
- Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 1999;117:794–801
- Weinreb RN, Lindsey JD. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci 2002;43:716–722
- Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol 2000;11:112–115
- Aihara M. Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clin Ophthalmol 2010;4:163–170
- Sen E, Nalcacioglu P, Yazici A, Aksakal FN, Altinok A, Tuna T, et al. Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. J Glaucoma 2008;17:398–402
- Schlote T, Tzamalis A, Kynigopoulos M. Central corneal thickness during treatment with travoprost 0.004% in glaucoma patients. J Ocul Pharmacol Ther 2009;25:459–462
- Hatanaka M, Vessani RM, Elias IR, Morita C, Susanna R, Jr. The effect of prostaglandin analogs and prostamide on central corneal thickness. J Ocul Pharmacol Ther 2009;25:51–53
- Bafa M, Georgopoulos G, Mihas C, Stavrakas P, Papaconstantinou D, Vergados I. The effect of prostaglandin analogues on central corneal thickness of patients with chronic open-angle glaucoma: a 2-year study on 129 eyes. Acta Ophthalmol 2011;89:448–451